The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations.
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Roche/Genentech
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche/Genentech
Carola Berking
Honoraria - Novartis
Sanjiv S Agarwala
Honoraria - Novartis
Dirk Schadendorf
No relevant relationships to disclose
Carla Van Herpen
No relevant relationships to disclose
Paola Queirolo
No relevant relationships to disclose
Christian U. Blank
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Axel Hauschild
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
J. Thaddeus Beck
Research Funding - Novartis
Angela Zubel
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Faiz Niazi
Employment or Leadership Position - Novartis
Simon Wandel
Employment or Leadership Position - Novartis
Reinhard Dummer
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis